Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Journal of Caffeine and Adenosine Research (formerly Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science) is a peer-reviewed journal encompassing all aspects of adenosine, from the molecular structure and function of receptors, enzymes and transporters, to the biochemistry, physiology and pharmacology of adenosine signaling; from the physiological role of adenosine in neuromodulation, inflammation and innate immunity, to its pathophysiological role in neuropsychiatric disorders and cancer. In addition, the Journal holds special interest in caffeine, the adenosine receptor antagonist that constitutes the most consumed psychoactive drug in the world.
The Journal does not publish articles that have been submitted or published elsewhere.
Journal of Caffeine and Adenosine Research coverage includes:
- Molecular biology
- Biochemistry and pharmacology
- Medicinal chemistry
- Neurophysiology, epilepsy and movement disorders
- Cognition and neurodegenerative disorders
- Psychiatric disorders
- Sleep and sleep disorders
- Cancer and Inflammation
- Cardiovascular function and disease
- Preclinical and clinical research
Manuscripts must be submitted online using the following URL http://mc.manuscriptcentral.com/caffeine
Please read all the instructions to authors before submitting.
SPECIAL OPEN ACCESS publishing option -- Contact: OpenAccess@liebertpub.com
SUBMISSION OF MANUSCRIPT
Please read all the instructions to authors before submitting.
Be prepared to enter:
- The title of the article.
- You will be asked to enter the full names and institutional affiliations of all authors, the name (with complete address, phone and fax numbers, and e-mail address) to whom correspondence should be directed.
- A running title of no more than 45 characters (including spaces).
- Provide a structured Abstract of no more than 250 words, stating the background, methods, results (including the sample size), and conclusions drawn from the study.
- You will be asked to enter 3–5 keywords or phrases.
You will also be asked for the names and e-mail addresses of at least five potential preferred reviewers familiar with the field. Please make sure preferred reviewers are not from your university or institution with whom you have collaborated. Anyone whom the author does not want to be considered should also be named as a non-preferred reviewer.
The author will also be asked to confirm that the material has not been published or submitted for publication elsewhere. All material published in the Journal will be copyrighted by Mary Ann Liebert, Inc.
All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results.
PREPARATION OF MANUSCRIPT
All manuscripts must be prepared in accordance with the "Uniform Requirements for Manuscripts Submitted for Biomedical Journals." Prepare text in double-spaced format in Microsoft Word. Leave ample margins on the sides, top, and bottom of pages. The order of items in the manuscript is: title page, abstract, text, acknowledgment(s), disclosure(s), references, reprint address, legends, and tables. Each page, including the title page, must be numbered in the upper right-hand corner. Number pages consecutively.
Text. Maximum word count should not exceed 4000 words. In General, the text should be organized under the headings: Introduction, Materials and Methods, Results, Discussion, and Conclusions. Use only standard abbreviations, which can be found in the AMA’s Manual for Authors & Editors or the Council of Biology Editors Style Manual. At first usage, spell out terms and give abbreviations in parentheses. Thereafter, use only abbreviations. It is not necessary to spell out standard units of measure, even at first usage. Use generic names for drugs if possible. If you wish to use a proprietary drug name the first time it appears, use the generic name followed by the proprietary name and manufacturer in parentheses.
Acknowledgments. The author should acknowledge only those people and their institutions that have made significant contributions to the study.
Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the manuscript, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscript. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at www.icmje.org/index.htlm#conflicts for further guidance. If no conflicts exist, all authors must state “No competing financial interests exist."
PUBLICATION ETHICS AND MALPRACTICE STATEMENT
If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients. The Journal does not provide a generic patient release form.
Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.]] Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.
In keeping with patients' rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests they have received and archived written patient consent.
Ethics of Experimentation
All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/.)
Ethical Treatment of Animals
All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles, and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.
DEFINITIONS OF SCIENTIFIC MISCONDUCT
Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).
Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:
- Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.
Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
Material failure to comply with legislative and regulatory requirements affecting research:
Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
- Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
- Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.
- Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.
Responding to Allegations of Possible Misconduct
The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.
When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.
Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.
If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.
All allegations will be kept confidential.
Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.
References. References must be prepared double spaced and numbered consecutively as they are cited in the text (using superscript numbers in text). References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned. Use journal abbreviations as provided by MEDLINE, National Library of Medicine. List all authors when there are six or less. When there are more than six, list the first three, followed by et al. If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (F. P. Haseltine, personal communication). Include, among the references, papers accepted but not yet published; designate the journal, and add "In Press."
Sample references are:
• Journal article:
Morelli M, Simola N. Can dietary substances protect against Parkinson's disease? The case of caffeine. Exp Neurol. 2010;225:246-249.
Higdon J. An Evidence-Based Approach to Dietary Phytochemicals. Germany: Thieme Georg Verlag; 2006.
Chapter in an Edited Book:
Myers JP, Johnson DA, McVey DD. Caffiene in the modulation of brain function. In: Caffeine and Behavior: Current Views and Research Trends. B.S. Gupta and Uma Gupta (Eds). Boca Raton, FL: CRC Press; 1999: pp. 17-30.
Reprint Address. Following the references, provide the name and complete address of the person to whom reprint requests should be sent.
Tables. Prepare tables double spaced, each as a separate file, and provide a title for each table. Cite tables in sequence in the text. Define abbreviations used in the body of the table in table footnotes. If a table is taken from a copyrighted publication, credit must be given in a footnote.
Figures. Cite figures consecutively in the manuscript within parentheses: A legend should be supplied for each illustration, and all legends numbered consecutively and provided (double spaced). Figures should be numbered in the order cited in the text. Images should not show the name of the manufacturer.
When naming your figure files, please label them with the corresponding author’s last name, followed by a period (.), and then list the figure number. Ex: Jones.Fig1.
Electronic submission of art follows these caveats:
• Do not include any illustrations as part of your text file.
• Do not prepare any figures in Word as they are not workable.
• Line illustrations must be submitted at 900 DPI.
• Halftones and color photos should be submitted at a minimum of 300 DPI.
• Adobe is the preferred software. Do NOT submit PowerPoint files.
• Save art as either TIFF or EPS files. Avoid submitting JPEG files.
• Color art must be saved as CYMK not RGB.
Legends. You may enter the legends for each image as you upload each individual file, or you may upload a separate file for legends. Each legend for illustrations must be double spaced. In the legend, provide explanations for any abbreviations, arrows, etc. on the art work. If the illustration is taken from a copyrighted publication, permission must be procured by the authors, and credit must be given in the legend. A full citation for the credited work should be provided in the reference section as a numbered reference.
LETTERS TO THE EDITOR(S):
Letters to the Editor(s) are welcomed, but with a 500-word limit and no more than one (1) table OR figure, and with a maximum of four (4) references.
The author(s) must secure written permission for any reprinted material. Materials taken from other sources must be accompanied by a written statement from the copyright holder (usually the publisher) giving permission to Journal of Caffeine and Adenosine Research for reproduction. If clearance is required by the author’s institution, statements concerning such clearance should be provided in the manuscript. Obtain and submit written permission from authors to cite unpublished data or papers still in press.
An e-mail containing a link to the PDF file of the page proof is sent to the corresponding author. The proof should be read carefully and returned promptly to the Publisher with the author’s approval and/or corrections.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740–2100; Fax: (914) 740–2101; E-mail: email@example.com; Website: www.liebertpub.com
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email firstname.lastname@example.org.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email email@example.com or visit Liebert Open Access for more information.